CLEVIPREX (clevidipine injectable emulsion) 50 mg/100 mL (0.5 mg/mL) recall — Chiesi Usa, Inc. (Class II)

Chiesi Usa, Inc. is recorded by the U.S. Food and Drug Administration (FDA) as recalling CLEVIPREX (clevidipine injectable emulsion) 50 mg/100 mL (0.5 mg/mL) — a Class II recall, initiated 2026-07-06 and posted to the FDA enforcement report on 2026-07-22, under recall number D-0689-2026. Status Ongoing, with no termination date on the record. The reason the FDA record carries is, verbatim: “Lack of Assurance of Sterility”. From the product description, the form is injectable emulsion, the strengths given are 50 mg/100 mL and 0.5 mg/mL and it is marked Rx only. 1 National Drug Code number is printed in the record: 10122-611-10. Distribution is recorded as “Nationwide within the United States” — Nationwide (US), with the recalling firm on record in NC, United States. It is the only recall number the FDA has filed under event ID 99376. Values are reproduced from the linked openFDA report; regulatory information, not medical advice.

Regulatory snapshot

Recall number D-0689-2026
FDA event ID 99376
Classification Class II (intermediate regulatory tier)
Status Ongoing
Recalling firm Chiesi Usa, Inc.
Recall initiated 2026-07-06
Reported by FDA 2026-07-22
Report lag 16 days from initiation to report
Distribution Nationwide within the United States — Nationwide (US)
Firm location on record NC, United States
Product description (source) CLEVIPREX (clevidipine injectable emulsion) 50 mg/100 mL (0.5 mg/mL), 10 Single Use Vials, Rx Only, Manufactured for: Chiesi USA, Inc., Cary, NC 27518, by Fresenius Kabi, Graz, Austria, NDC 10122-611-10.

Reason reported by FDA

Lack of Assurance of Sterility

5 words from the enforcement report field reason_for_recall, reproduced without edit — the firm's own wording, not an assessment.

Product identifiers in this record

6 identifying values matched by exact pattern in the 30-word product description above; each is a literal substring of it.

Product named CLEVIPREX (clevidipine injectable emulsion) 50 mg/100 mL (0.5 mg/mL)
Form Injectable Emulsion
Strength 50 mg/100 mL · 0.5 mg/mL
NDC 10122-611-10
Marketing category Rx only
Manufactured for Chiesi USA, Inc.

Reported in the same month (2026-07)

111 enforcement reports carry a report date in 2026-07; these 8 are the Class II ones nearest this record.

Recall recordRecall numberRecalling firmFDA tierReported
Nystatin Cream USP, 15 gD-0677-2026Padagis US LLCClass II2026-07-22
CVS Health, 6.5%D-0678-2026Bell Pharmaceuticals, IncClass II2026-07-22
Clinere, 0.50 mLD-0679-2026Bell Pharmaceuticals, IncClass II2026-07-22
QC Quality Choice, 6.5%D-0680-2026Bell Pharmaceuticals, IncClass II2026-07-22
TopCare Health, 6.5%D-0681-2026Bell Pharmaceuticals, IncClass II2026-07-22
AUDIOLOGIST'S CHOICE, 6.5%D-0682-2026Bell Pharmaceuticals, IncClass II2026-07-22
FAMILY Wellness, 6.5%D-0683-2026Bell Pharmaceuticals, IncClass II2026-07-22
GOOD NEIGHBOR PHARMACY, 6.5%D-0684-2026Bell Pharmaceuticals, IncClass II2026-07-22

Nearest Class II recalls by date

213 of 250 indexed records share the Class II tier; the 8 nearest to 2026-07-22 by report date are listed here.

Recall recordRecall numberRecalling firmStrength / formReported
LEADER, 6.5%D-0685-2026Bell Pharmaceuticals, Inc6.5% · Drops2026-07-22
Foster & Thrive, 6.5%D-0686-2026Bell Pharmaceuticals, Inc6.5%2026-07-22
meijer, 6.5%D-0687-2026Bell Pharmaceuticals, Inc6.5%2026-07-22
CAREone, 6.5%D-0688-2026Bell Pharmaceuticals, Inc6.5%2026-07-22
BD ChloraPrep Clear, 2%D-0690-2026Carefusion 213, LLC2% · Solution2026-07-22
Methohexital Sodium for Injection, 500 mgD-0662-2026Onesource Specialty Pharma Ltd500 mg · for Injection2026-07-15
Medline Remedy Specialized Silicone Cream (Hydraguard-D ), 59 mLD-0663-2026Biomed Laboratories, Llc.59 mL · Cream2026-07-15
Methohexital Sodium, 100 mg/10 mLD-0664-2026Quva Pharma, Inc.100 mg/10 mL2026-07-15

Reading this record

Class II is the FDA's own severity tier for the recall action — 213 of the 250 indexed records carry it — and it describes the agency's assessment of the action, not a risk statement about any individual. Match a package against 10122-611-10 at the FDA source to confirm it is covered.

Namespace context: the Class II index (213 records) and the recall hub (250 records, 118 FDA events); Chiesi Usa, Inc. (1 indexed records) aggregates this firm across datasets.

Coverage and limits of this record

This page reflects the openFDA enforcement report for D-0689-2026 as ingested on 2026-08-22, which can lag the live FDA record and omits detail held only in primary documents. It offers no clinical assessment, no advice about whether to use any product, and no substitute. For any health question consult a qualified healthcare professional.

Source & provenance

Official source
https://api.fda.gov/drug/enforcement.json?search=recall_number:%22D-0689-2026%22
Source dataset
openFDA Drug Enforcement API
Publication date
2026-07-22
Ingested
2026-08-22
Record hash
9849a7710d08399d

Verify every value against the official FDA source above. This site links to the regulator's record rather than replacing it.